Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Bristol-Myers Squibb Company

Bristol-Myers Squibb Company Stock price

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 21:00:02 06/12/2023 GMT 		Intraday chart for Bristol-Myers Squibb Company 5-day change 1st Jan Change
49.88 USD -0.70% +2.38% -30.67%
09:52am Bristol Myers: 5% dividend increase CF
12-06 Bristol-Myers Squibb Raises Quarterly Dividend to $0.60 a Share from $0.57, Payable on Feb. 1 to Shareholders as of Jan. 5 MT

Financials

Sales 2023 * 44.79B 3,560B Sales 2024 * 45.9B 3,648B Capitalization 101B 8,067B
Net income 2023 * 7.96B 633B Net income 2024 * 7.29B 579B EV / Sales 2023 *
2,82x
Net Debt 2023 * 24.94B 1,982B Net Debt 2024 * 16.87B 1,341B EV / Sales 2024 *
2,58x
P/E ratio 2023 *
13,2x
P/E ratio 2024 *
12,5x
Employees 34,300
Yield 2023 *
4,57%
Yield 2024 *
4,78%
Free-Float 69.53%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Bristol Myers: 5% dividend increase CF
Bristol-Myers Squibb Raises Quarterly Dividend to $0.60 a Share from $0.57, Payable on Feb. 1 to Shareholders as of Jan. 5 MT
Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents DJ
Bristol-Myers Squibb Company Declares Quarterly Dividend on Common Stock, Payable on February 1, 2024 CI
UniCredit seeks new chair candidate by early 2024, sources say RE
IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Diseases CI
UniCredit seeks new chair candidate by early 2024, sources say RE
Bristol-Myers Squibb Says Application for Bladder Cancer Combo Therapy Gets Priority Review Status From US FDA MT
Bristol Myers Gets FDA Priority Review of Opdivo-Chemotherapy Combo in Bladder Cancer DJ
Bristol Myers: priority review status granted for Opdivo CF
Bristol Myers Squibb Announces U.S. Food and Drug Administration Accept the Supplemental Biologics License Application for Opdivo CI
Blackstone explores sale of Anthos Therapeutics -sources RE
Blackstone explores sale of Anthos Therapeutics -sources RE
Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing MT
US FDA investigating safety risk of CAR-T cancer therapies RE
More news

Analyst Recommendations on Bristol-Myers Squibb Company

Cantor Fitzgerald Downgrades Bristol-Myers Squibb to Neutral From Overweight, Cuts Price Target to $55 From $68 MT
Deutsche Bank Initiates Coverage on Bristol-Myers Squibb With Hold Rating, $55 Price Target MT
Daiwa Securities Downgrades Bristol-Myers Squibb to Neutral From Outperform, Adjusts Price Target to $54 From $68 MT
Berenberg Bank Adjusts Bristol-Myers Squibb Price Target to $60 From $76, Maintains Hold Rating MT
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $69 From $81, Maintains Buy Rating MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb Announces Dividend Increase BU
Bristol Myers Squibb : Abecma® Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in Japan PU
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients AQ
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic... BU
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology AQ
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : augmentation de 5% du dividende
UniCredit cerca nuovo candidato alla presidenza entro inizio 2024 - fonti
Bristol Myers : un examen prioritaire obtenu pour Opdivo
Blackstone explora la venta de Anthos Therapeutics: fuentes
Bayer anticipe des impacts sur sa trésorerie après l'échec clinique de son anticoagulant
More news

Quotes and Performance

1 day-0.70%
1 week+2.38%
Current month+1.01%
1 month-5.51%
3 months-16.41%
6 months-23.82%
Current year-30.67%
More quotes

Highs and lows

1 week
48.93
Extreme 48.93
50.76
1 month
48.25
Extreme 48.252
52.58
Current year
48.25
Extreme 48.252
75.18
1 year
48.25
Extreme 48.252
80.67
3 years
48.25
Extreme 48.252
81.44
5 years
42.48
Extreme 42.48
81.44
10 years
42.48
Extreme 42.48
81.44
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 52 2015
Giovanni Caforio CHM
 Chairman 58 1999
David Elkins DFI
 Director of Finance/CFO 54 2019
Members of the board TitleAgeSince
Phyllis R. Yale BRD
 Director/Board Member 65 2019
Peter Arduini BRD
 Director/Board Member 58 2016
Derica Rice BRD
 Director/Board Member 58 2020
More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
12.97% 323 M€ -7.50% -
FIRST TRUST NASDAQ PHARMACEUTICALS ETF - USD ETF First Trust Nasdaq Pharmaceuticals ETF - USD
6.42% 18 M€ -7.82% -
HORIZON KINETICS MEDICAL ETF - USD ETF Horizon Kinetics Medical ETF - USD
6.03% 16 M€ 0.00% -
HARVEST HEALTHCARE LEADERS INCOME ETF - CAD HEDGED ETF Harvest Healthcare Leaders Income ETF - CAD Hedged
5.00% 820 M€ -4.99% -
More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date Price Change Volume
06/12/23 49.88 -0.70% 13,839,803
05/12/23 50.23 +0.50% 12,659,509
04/12/23 49.98 -0.24% 14,238,572
01/12/23 50.1 +1.46% 12,806,403
30/11/23 49.38 +1.35% 17,044,327

Delayed Quote Nyse, December 06, 2023 at 09:00 pm

More quotes

Company Profile

More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
49.88USD
Average target price
64.13USD
Spread / Average Target
+28.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-30.67% 101 B $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.07% 530 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.52% 438 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-11.34% 377 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-4.79% 268 B $
ABBVIE INC. Stock AbbVie Inc.
-9.42% 258 B $
NOVARTIS AG Stock Novartis AG
+0.86% 200 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-9.65% 198 B $
PFIZER, INC. Stock Pfizer, Inc.
-43.81% 163 B $
AMGEN INC. Stock Amgen Inc.
+2.55% 144 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer
Etats-Unis

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition